Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

722
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
722
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

606
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

571
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
571
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

910
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
910
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

299
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
299

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vulvar findings and sexual dysfunction in women with systemic sclerosis.

JAAD international·2026
Same author

Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study.

Journal of clinical medicine·2026
Same author

Condensation of the lower part of the iliac bone.

Joint bone spine·2026
Same author

Artificial Intelligence in Rheumatology: From Algorithms to Clinical Impact in Osteoporosis and Chronic Inflammatory Rheumatic Diseases.

Journal of clinical medicine·2026
Same author

Impaired organic and mineral extracellular matrix composition in early-onset osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.

The Lancet. Rheumatology·2025
Same journal

Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.

Pharmacology·2026
Same journal

Retraction Statement.

Pharmacology·2026
Same journal

Antiplatelet Therapy After Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis.

Pharmacology·2026
Same journal

Ciprofol versus Propofol for General Anesthesia Induction in Major Orthopedic Surgery: Efficacy and Safety Analyses Pertaining to Anesthetic Parameters.

Pharmacology·2026
Same journal

Sappanone A targets TFEB to promote lysosomal autophagy and attenuate high glucose-induced myocardial injury.

Pharmacology·2026
Same journal

Tocilizumab Biosimilars Versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity.

Pharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.

Marie Fechtenbaum1, Pauline Lasselin-Boyard, Sarah Salomon

  • 1Department of Rheumatology, CHU Amiens, Amiens, France.

Pharmacology
|April 27, 2016
PubMed
Summary
This summary is machine-generated.

Tocilizumab (TCZ) showed efficacy in rheumatoid arthritis (RA) patients. A dose reduction from 8 to 4 mg/kg resulted in higher remission rates and fewer severe infections compared to a stable 8 mg/kg dose.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Tocilizumab (TCZ) is an established treatment for rheumatoid arthritis (RA).
  • Intravenous doses of 4 and 8 mg/kg are commonly administered.
  • Real-world data on TCZ dosing strategies in RA are valuable.

Purpose of the Study:

  • To evaluate the efficacy and safety of TCZ in RA patients.
  • To compare a stable 8 mg/kg TCZ dose with a dose reduction from 8 to 4 mg/kg.
  • To assess clinical remission and adverse event rates in different TCZ dosing regimens.

Main Methods:

  • Retrospective analysis of RA patients treated with TCZ from January 2010 to December 2014.
  • Two patient groups: one receiving 8 mg/kg TCZ, another receiving 8 mg/kg followed by 4 mg/kg.
  • Data collected included demographics, clinical response (Disease Activity Score 28), and adverse events.

Main Results:

  • Clinical remission rates were 48% in the 8 mg/kg group and 74% in the 8-4 mg/kg group.
  • Severe infection rates were 4.8 per 100 patient-years (PY) for the 8 mg/kg group and 2.9 per 100 PY for the 8-4 mg/kg group.
  • Predominant infections included pulmonary, ENT, and skin infections.

Conclusions:

  • The 8 then 4 mg/kg TCZ dosing strategy demonstrated higher efficacy in achieving clinical remission in RA patients.
  • This dose reduction strategy also showed a favorable safety profile with lower rates of severe infections.
  • Real-world evidence supports the effectiveness and safety of TCZ in RA management.